NYSE:EW Edwards Lifesciences (EW) Stock Forecast, Price & News $87.93 +0.52 (+0.59%) (As of 05/19/2023 08:48 PM ET) Add Compare Share Share Today's Range$87.19▼$88.3150-Day Range$76.62▼$89.1852-Week Range$67.13▼$107.92Volume3.00 million shsAverage Volume3.21 million shsMarket Capitalization$53.30 billionP/E Ratio36.49Dividend YieldN/APrice Target$89.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Edwards Lifesciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside1.9% Upside$89.63 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.74Based on 7 Articles This WeekInsider TradingSelling Shares$15.69 M Sold Last QuarterProj. Earnings Growth12.55%From $2.55 to $2.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector122nd out of 971 stocksSurgical Appliances & Supplies Industry7th out of 19 stocks 2.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 7 buy ratings, 10 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $89.63, Edwards Lifesciences has a forecasted upside of 1.9% from its current price of $87.93.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.53% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 27.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.1 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.Search InterestOnly 13 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,691,418.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions80.35% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.55% in the coming year, from $2.55 to $2.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 36.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 36.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.96.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.97. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 8.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edwards Lifesciences (NYSE:EW) StockEdwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.Read More Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Stock News HeadlinesMay 21, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Research Coverage Started at StockNews.comMay 17, 2023 | finance.yahoo.comDATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETYMay 22, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 16, 2023 | marketwatch.com8-K: Edwards Lifesciences CorpMay 14, 2023 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) CFO Sells $7,145,178.00 in StockMay 11, 2023 | msn.comWill Investors Notice Exciting Sign On Edwards Lifesciences's Chart?May 11, 2023 | finance.yahoo.comNuVasive (NUVA) Q1 Earnings Beat Estimates, Margins FallMay 11, 2023 | finance.yahoo.comCharles River (CRL) Q1 Earnings Top Estimates, View NarrowedMay 22, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 11, 2023 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $499,373.70 in StockMay 10, 2023 | finance.yahoo.comExact Sciences (EXAS) Q1 Earnings Top, Sales View RaisedMay 10, 2023 | americanbankingnews.comAnalyzing Edwards Lifesciences (NYSE:EW) & Pathfinder Cell Therapy (OTCMKTS:PFND)May 10, 2023 | americanbankingnews.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 6,640 Shares of StockMay 9, 2023 | marketwatch.comEdwards Lifesciences Corp. stock falls Tuesday, still outperforms marketMay 9, 2023 | finance.yahoo.comBruker's (BRKR) New Buyout to Advance Digital TransformationMay 8, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Receives Reiterates Rating from 92 ResourcesMay 7, 2023 | markets.businessinsider.comEdwards:Aortic Valve With Resilia Tissue Shows Favorable Durability& Efficacy Outcomes In 7-yrs DataMay 7, 2023 | finance.yahoo.comInvestingPro exclusive: 5 biotech beasts to get your hands onMay 5, 2023 | marketwatch.comEdwards Lifesciences Corp. stock rises Friday, still underperforms marketMay 5, 2023 | finance.yahoo.comGlobus Medical (GMED) Q1 Earnings Beat, Operating Margin DipsMay 5, 2023 | finance.yahoo.comBruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 OutlookMay 5, 2023 | markets.businessinsider.comCredit Suisse Sticks to Its Hold Rating for Edwards Lifesciences (EW)May 4, 2023 | marketwatch.comEdwards Lifesciences Corp. stock falls Thursday, still outperforms marketMay 4, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)May 4, 2023 | msn.comRBC Capital Reiterates Edwards Lifesciences (EW) Outperform RecommendationMay 4, 2023 | finance.yahoo.comQuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View RevisedMay 4, 2023 | finance.yahoo.comInari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/YSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Company Calendar Last Earnings4/26/2023Today5/21/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees17,300Year Founded1958Price Target and Rating Average Stock Price Forecast$89.63 High Stock Price Forecast$110.00 Low Stock Price Forecast$66.00 Forecasted Upside/Downside+1.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$2.41 Trailing P/E Ratio36.49 Forward P/E Ratio34.48 P/E Growth4.97Net Income$1.52 billion Net Margins27.07% Pretax Margin31.45% Return on Equity25.81% Return on Assets18.24% Debt Debt-to-Equity Ratio0.10 Current Ratio3.01 Quick Ratio2.17 Sales & Book Value Annual Sales$5.38 billion Price / Sales9.90 Cash Flow$2.75 per share Price / Cash Flow31.97 Book Value$10.00 per share Price / Book8.79Miscellaneous Outstanding Shares606,220,000Free Float598,398,000Market Cap$53.30 billion OptionableOptionable Beta1.02 Social Links Key ExecutivesMichael A. MussallemChairman & Chief Executive OfficerBernard J. ZovighianPresidentScott B. UllemChief Financial Officer & Vice PresidentTodd J. BrintonChief Scientific Officer & VP-Advanced TechnologyLinda J. ParkSecretary, Senior VP & Associate General CounselKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNSmith & NephewNYSE:SNNView All CompetitorsInsiders & InstitutionsCentaurus Financial Inc.Bought 797 shares on 5/18/2023Ownership: 0.001%Chevy Chase Trust Holdings LLCBought 3,417 shares on 5/17/2023Ownership: 0.060%Advisory Services Network LLCSold 11,233 shares on 5/17/2023Ownership: 0.005%B. Riley Wealth Advisors Inc.Sold 13,320 shares on 5/17/2023Ownership: 0.004%Sunbelt Securities Inc.Bought 600 shares on 5/17/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EW Stock - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price forecast for 2023? 18 brokers have issued 1 year target prices for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $110.00. On average, they predict the company's stock price to reach $89.63 in the next year. This suggests a possible upside of 1.9% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2023? Edwards Lifesciences' stock was trading at $74.61 at the start of the year. Since then, EW stock has increased by 17.9% and is now trading at $87.93. View the best growth stocks for 2023 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a drop in short interest in April. As of April 30th, there was short interest totaling 9,180,000 shares, a drop of 27.3% from the April 15th total of 12,620,000 shares. Based on an average daily volume of 3,230,000 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.5% of the company's shares are short sold. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Wednesday, April, 26th. The medical research company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.01. The medical research company had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.39 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.81% and a net margin of 27.07%. The business's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 earnings per share. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), Neuberger Berman Disrupters ETF (NBDS), Hennessy Stance ESG Large Cap ETF (STNC), Goldman Sachs Future Health Care Equity ETF (GDOC), Global X Aging Population ETF (AGNG), ETC 6 Meridian Quality Growth ETF (SXQG) and Inspire 100 ETF (BIBL). When did Edwards Lifesciences' stock split? Edwards Lifesciences's stock split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its FY23 earnings guidance on Wednesday, April, 26th. The company provided earnings per share guidance of $2.48-$2.60 for the period, compared to the consensus EPS estimate of $2.51. The company issued revenue guidance of $5.6-$6.0 billion, compared to the consensus revenue estimate of $5.85 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.51%), State Street Corp (4.44%), Bank of New York Mellon Corp (3.00%), Wellington Management Group LLP (2.61%), Brown Advisory Inc. (2.32%) and Geode Capital Management LLC (2.01%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $87.93. How much money does Edwards Lifesciences make? Edwards Lifesciences (NYSE:EW) has a market capitalization of $53.30 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.41 on an earnings per share basis. How many employees does Edwards Lifesciences have? The company employs 17,300 workers across the globe. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More How can I contact Edwards Lifesciences? Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525. This page (NYSE:EW) was last updated on 5/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.